Erasca Inc
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in SEACRAFT-2 pivotal Phase 3 trial for patients with NRAS-mutated (NRASm) melanoma; and in SEACRAFT-1 Phase 1b trial for patients with NRAS Q61X melanoma. It also develops… Read more
Erasca Inc (ERAS) - Net Assets
Latest net assets as of September 2025: $347.89 Million USD
Based on the latest financial reports, Erasca Inc (ERAS) has net assets worth $347.89 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($420.40 Million) and total liabilities ($72.52 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $347.89 Million |
| % of Total Assets | 82.75% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 24.27 |
Erasca Inc - Net Assets Trend (2019–2024)
This chart illustrates how Erasca Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Erasca Inc (2019–2024)
The table below shows the annual net assets of Erasca Inc from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $423.50 Million | +33.73% |
| 2023-12-31 | $316.69 Million | -23.11% |
| 2022-12-31 | $411.85 Million | -9.79% |
| 2021-12-31 | $456.53 Million | +500.52% |
| 2020-12-31 | $-113.98 Million | -737.87% |
| 2019-12-31 | $-13.60 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Erasca Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 75392100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $28.00K | 0.01% |
| Other Comprehensive Income | $405.00K | 0.10% |
| Other Components | $1.19 Billion | 281.16% |
| Total Equity | $423.50 Million | 100.00% |
Erasca Inc Competitors by Market Cap
The table below lists competitors of Erasca Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
International Seaways Inc
NYSE:INSW
|
$2.73 Billion |
|
Solaris Energy Infrastructure, Inc.
NYSE:SEI
|
$2.73 Billion |
|
Loomis AB (publ)
PINK:LOIMF
|
$2.73 Billion |
|
Inner Mongolia Junzheng Energy & Chemical Group Co Ltd
SHG:601216
|
$2.74 Billion |
|
BRP Inc
NASDAQ:DOOO
|
$2.73 Billion |
|
Fastly, Inc. Class A Common Stock
NYSE:FSLY
|
$2.73 Billion |
|
Wuhan Jingce Electronic Technology Co Ltd
SHE:300567
|
$2.73 Billion |
|
Black Stone Minerals LP
NYSE:BSM
|
$2.73 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Erasca Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 316,686,000 to 423,499,000, a change of 106,813,000 (33.7%).
- Net loss of 161,650,000 reduced equity.
- Share repurchases of 800,000 reduced equity.
- New share issuances of 239,061,000 increased equity.
- Other comprehensive income increased equity by 328,000.
- Other factors increased equity by 29,874,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-161.65 Million | -38.17% |
| Share Repurchases | $800.00K | -0.19% |
| Share Issuances | $239.06 Million | +56.45% |
| Other Comprehensive Income | $328.00K | +0.08% |
| Other Changes | $29.87 Million | +7.05% |
| Total Change | $- | 33.73% |
Book Value vs Market Value Analysis
This analysis compares Erasca Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.38x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-0.14 | $13.36 | x |
| 2020-12-31 | $-6.14 | $13.36 | x |
| 2021-12-31 | $-2.50 | $13.36 | x |
| 2022-12-31 | $-4.93 | $13.36 | x |
| 2023-12-31 | $2.64 | $13.36 | x |
| 2024-12-31 | $1.81 | $13.36 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Erasca Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -38.17%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.19x
- Recent ROE (-38.17%) is below the historical average (-12.94%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-10.68 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-90.26 Million |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-98.95 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-194.71 Million |
| 2023 | -39.48% | 0.00% | 0.00x | 1.25x | $-156.71 Million |
| 2024 | -38.17% | 0.00% | 0.00x | 1.19x | $-204.00 Million |
Industry Comparison
This section compares Erasca Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Erasca Inc (ERAS) | $347.89 Million | 0.00% | 0.21x | $2.73 Billion |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |